Sign In
Buy MKL
Markel Earnings Calls
| Release date | Apr 28, 2026 |
| EPS estimate | $26.38 |
| EPS actual | $21.61 |
| EPS Surprise | -18.08% |
| Revenue estimate | 3.66B |
| Revenue actual | 2.823B |
| Revenue Surprise | -22.86% |
| Release date | Feb 04, 2026 |
| EPS estimate | $27.62 |
| EPS actual | $34.45 |
| EPS Surprise | 24.73% |
| Revenue estimate | 3.64B |
| Revenue actual | 4.22B |
| Revenue Surprise | 15.93% |
| Release date | Oct 29, 2025 |
| EPS estimate | $24.02 |
| EPS actual | $30.90 |
| EPS Surprise | 28.64% |
| Revenue estimate | 3.749B |
| Revenue actual | 4.387B |
| Revenue Surprise | 17.00% |
| Release date | Jul 30, 2025 |
| EPS estimate | $24.97 |
| EPS actual | $25.46 |
| EPS Surprise | 1.96% |
| Revenue estimate | 4.824B |
| Revenue actual | 4.411B |
| Revenue Surprise | -8.56% |
Last 4 Quarters for Markel
Below you can see how MKL performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jul 30, 2025 |
| Price on release | $2,006.57 |
| EPS estimate | $24.97 |
| EPS actual | $25.46 |
| EPS surprise | 1.96% |
| Date | Price |
|---|---|
| Jul 24, 2025 | $2,003.45 |
| Jul 25, 2025 | $2,026.69 |
| Jul 28, 2025 | $2,011.91 |
| Jul 29, 2025 | $2,018.50 |
| Jul 30, 2025 | $2,006.57 |
| Jul 31, 2025 | $2,008.29 |
| Aug 01, 2025 | $1,929.87 |
| Aug 04, 2025 | $1,946.42 |
| Aug 05, 2025 | $1,938.58 |
| 4 days before | 0.156% |
| 4 days after | -3.39% |
| On release day | 0.0857% |
| Change in period | -3.24% |
| Release date | Oct 29, 2025 |
| Price on release | $1,826.32 |
| EPS estimate | $24.02 |
| EPS actual | $30.90 |
| EPS surprise | 28.64% |
| Date | Price |
|---|---|
| Oct 23, 2025 | $1,896.18 |
| Oct 24, 2025 | $1,878.89 |
| Oct 27, 2025 | $1,883.32 |
| Oct 28, 2025 | $1,837.96 |
| Oct 29, 2025 | $1,826.32 |
| Oct 30, 2025 | $1,938.38 |
| Oct 31, 2025 | $1,974.53 |
| Nov 03, 2025 | $1,955.11 |
| Nov 04, 2025 | $1,981.81 |
| 4 days before | -3.68% |
| 4 days after | 8.51% |
| On release day | 6.14% |
| Change in period | 4.52% |
| Release date | Feb 04, 2026 |
| Price on release | $2,054.08 |
| EPS estimate | $27.62 |
| EPS actual | $34.45 |
| EPS surprise | 24.73% |
| Date | Price |
|---|---|
| Jan 29, 2026 | $2,020.62 |
| Jan 30, 2026 | $2,040.64 |
| Feb 02, 2026 | $2,033.99 |
| Feb 03, 2026 | $2,038.65 |
| Feb 04, 2026 | $2,054.08 |
| Feb 05, 2026 | $2,095.03 |
| Feb 06, 2026 | $2,102.15 |
| Feb 09, 2026 | $2,076.45 |
| Feb 10, 2026 | $2,103.20 |
| 4 days before | 1.66% |
| 4 days after | 2.39% |
| On release day | 1.99% |
| Change in period | 4.09% |
| Release date | Apr 28, 2026 |
| Price on release | $1,908.99 |
| EPS estimate | $26.38 |
| EPS actual | $21.61 |
| EPS surprise | -18.08% |
| Date | Price |
|---|---|
| Apr 22, 2026 | $1,944.03 |
| Apr 23, 2026 | $1,929.91 |
| Apr 24, 2026 | $1,912.45 |
| Apr 27, 2026 | $1,895.74 |
| Apr 28, 2026 | $1,908.99 |
| Apr 29, 2026 | $1,759.21 |
| Apr 30, 2026 | $1,772.47 |
| May 01, 2026 | $1,780.13 |
| May 04, 2026 | $1,751.37 |
| 4 days before | -1.80% |
| 4 days after | -8.26% |
| On release day | -7.85% |
| Change in period | -9.91% |
Markel Earnings Call Transcript Summary of Q1 2026
Markel Group reported Q1 2026 results showing continued progress in underwriting and a disciplined capital allocation stance. Consolidated operating revenues (excluding net investment gains) were $3.6 billion, and adjusted operating income was $498 million (up 4% year-over-year). Net investment losses drove GAAP operating income to a loss for the quarter, but management emphasizes these were unrealized market moves. Markel Insurance produced notable improvement: adjusted operating income for the insurance segment rose to $369 million, the insurance combined ratio improved to ~93% (92.8% reported), and adjusted underwriting gross written premiums were up 10% excluding the deliberate exits of Global Re and the Hagerty fronting change. The company exited a $1 billion global reinsurance business and transitioned Hagerty to a fronting model, reducing reported GWP but expected to improve combined ratio and ROE. International insurance grew strongly (+28% GWP, though management views that as a high-water mark and expects mid-teens growth going forward) and Programs and Solutions (adjusted for Hagerty) showed healthy growth. Management highlighted active re-underwriting in U.S. casualty/general liability—reducing average limits and construction exposure—to improve long-term profitability. The public equity portfolio declined in Q1 (unrealized loss), but Markel maintains a long-term, disciplined investment process and continues share repurchases ($134M repurchased in Q1; ~10% fewer shares outstanding vs. peak). Industrial and Consumer businesses showed mixed results: organic revenue growth in industrials but lower margins due to mix (soft end markets like transportation equipment), and a small impairment in the Financial segment (a $14M equity-method impairment). Management reiterated a strong balance sheet, high-quality fixed income portfolio, and optionality to deploy capital via repurchases, acquisitions, or building liquidity. Key risks discussed include cyclical softness in certain end markets, collateral shortfall in a State National-related fronting arrangement (management does not expect it to be material), and broader market volatility affecting unrealized investment marks.
